Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1).
暂无分享,去创建一个
G. Poda | C. Arrowsmith | M. Schapira | M. Vedadi | R. Al-awar | P. Brown | A. Dong | D. Smil | G. Senisterra | E. Kuznetsova | Matthäus Getlik | C. Zepeda-Velázquez | T. Kiyota | Hong Wu | L. Dombrovski | Y. Bolshan | R. Marcellus | T. Hajian | P. Brown | Matthäus Getlik | Ekaterina Kuznetsova | R. Al-Awar
[1] R. Roberts,et al. Human Genome and Diseases:¶WD-repeat proteins: structure characteristics, biological function, and their involvement in human diseases , 2001, Cellular and Molecular Life Sciences CMLS.
[2] Ø. Bruserud,et al. Animal models of acute myelogenous leukaemia – development, application and future perspectives , 2005, Leukemia.
[3] M. Cosgrove,et al. Structure of WDR5 Bound to Mixed Lineage Leukemia Protein-1 Peptide* , 2008, Journal of Biological Chemistry.
[4] M. Cosgrove,et al. A Conserved Arginine-containing Motif Crucial for the Assembly and Enzymatic Activity of the Mixed Lineage Leukemia Protein-1 Core Complex* , 2008, Journal of Biological Chemistry.
[5] J. Downing,et al. Mouse models of human AML accurately predict chemotherapy response. , 2009, Genes & development.
[6] R. Slany. The molecular biology of mixed lineage leukemia , 2009, Haematologica.
[7] B. Kuhn,et al. A Medicinal Chemist’s Guide to Molecular Interactions , 2010, Journal of medicinal chemistry.
[8] Elizabeth C. Townsend,et al. Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction. , 2010, Journal of medicinal chemistry.
[9] Nadine H. Elowe,et al. An allosteric inhibitor of substrate recognition by the SCFCdc4 ubiquitin ligase , 2010, Nature Biotechnology.
[10] W. Sippl,et al. Targeting epigenetic modifiers: Inhibitors of histone methyltransferases , 2010 .
[11] H. Shu,et al. MLL1/WDR5 complex in leukemogenesis and epigenetic regulation , 2011, Chinese journal of cancer.
[12] Liu Liu,et al. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction. , 2013, Journal of the American Chemical Society.
[13] G. Poda,et al. Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction. , 2013, ACS medicinal chemistry letters.
[14] G. Poda,et al. Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5 , 2012, The Biochemical journal.
[15] Zhaohui S. Qin,et al. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. , 2014, Molecular cell.
[16] R. C. Poulos,et al. WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma. , 2015, Cancer research.
[17] G. Poda,et al. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia , 2015, Nature chemical biology.
[18] Cheryl H. Arrowsmith,et al. Prevalent p53 mutants co-opt chromatin pathways to drive cancer growth , 2015, Nature.